Annexin Pharmaceuticals AB (ST:ANNX) — Stock Price
Annexin Pharmaceuticals AB (ST:ANNX) is currently trading at Skr12.25 SEK, down 3.16% today. Over the past 52 weeks, shares have ranged between Skr12.00 and Skr29.60. This page tracks Annexin Pharmaceuticals AB's live share price on the ST exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ANNX company net worth.
Annexin Pharmaceuticals AB (ANNX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Annexin Pharmaceuticals AB's daily closing share price and trading volume on the ST exchange over the past year, giving a clear view of recent price momentum and liquidity.
Annexin Pharmaceuticals AB Income Statement — Revenue, Profit & Earnings by Year
Annexin Pharmaceuticals AB's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 |
| Cost of Revenue | Skr48.00K | Skr193.00K | Skr193.00K | Skr193.00K | Skr192.00K |
| Gross Profit | Skr-48.00K | Skr-193.00K | Skr-193.00K | Skr-193.00K | Skr-192.00K |
| Research & Development | Skr26.24 Million | Skr40.81 Million | Skr36.02 Million | Skr28.37 Million | Skr42.13 Million |
| SG&A | Skr10.07 Million | Skr9.59 Million | Skr8.01 Million | Skr12.29 Million | Skr10.70 Million |
| Total Operating Expenses | Skr36.27 Million | Skr50.48 Million | Skr44.18 Million | Skr40.66 Million | Skr52.83 Million |
| Operating Income | Skr-36.31 Million | Skr-50.48 Million | Skr-44.18 Million | Skr-40.72 Million | Skr-51.23 Million |
| EBITDA | Skr-36.84 Million | Skr-50.20 Million | Skr-43.86 Million | Skr-40.72 Million | Skr-50.28 Million |
| EBIT | Skr-36.89 Million | Skr-50.40 Million | Skr-44.05 Million | Skr-40.72 Million | Skr-50.48 Million |
| Interest Expense | Skr0.00 | Skr53.00K | Skr104.00K | Skr2.00K | Skr1.86 Million |
| Income Before Tax | Skr-36.89 Million | Skr-50.25 Million | Skr-44.05 Million | Skr-40.73 Million | Skr-52.14 Million |
| Income Tax Expense | — | — | Skr137.00K | Skr-193.00K | Skr909.00K |
| Net Income | Skr-36.89 Million | Skr-50.25 Million | Skr-44.05 Million | Skr-40.73 Million | Skr-52.14 Million |
Annexin Pharmaceuticals AB Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Annexin Pharmaceuticals AB's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Skr30.16 Million | Skr19.04 Million | Skr26.76 Million | Skr36.68 Million | Skr52.79 Million |
| Total Current Assets | Skr28.57 Million | Skr17.38 Million | Skr24.91 Million | Skr33.65 Million | Skr50.72 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | Skr376.00K | Skr418.00K | Skr2.63 Million | Skr1.86 Million | Skr1.01 Million |
| Inventory | — | — | — | — | Skr1.00 |
| Property, Plant & Equipment | Skr1.12 Million | Skr1.08 Million | Skr1.17 Million | Skr1.26 Million | Skr1.35 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Skr5.22 Million | Skr5.32 Million | Skr7.95 Million | Skr6.53 Million | Skr6.06 Million |
| Total Current Liabilities | Skr5.22 Million | Skr5.32 Million | Skr7.95 Million | Skr6.53 Million | Skr6.06 Million |
| Long-term Debt | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 | Skr0.00 |
| Net Debt | Skr-27.39 Million | Skr-16.34 Million | Skr-21.41 Million | Skr-31.11 Million | Skr-49.48 Million |
| Total Stockholder Equity | Skr24.93 Million | Skr13.71 Million | Skr18.81 Million | Skr30.15 Million | Skr46.73 Million |
| Retained Earnings | Skr-373.36 Million | Skr-336.46 Million | Skr-286.21 Million | Skr-242.16 Million | Skr-201.63 Million |
Annexin Pharmaceuticals AB Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Annexin Pharmaceuticals AB generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Skr-36.92 Million | Skr-50.23 Million | Skr-43.40 Million | Skr-41.16 Million | Skr-45.02 Million |
| Capital Expenditures | Skr129.00K | Skr0.00 | Skr43.40 Million | Skr0.00 | Skr0.00 |
| Free Cash Flow | Skr-37.05 Million | Skr-50.23 Million | Skr-43.40 Million | Skr-41.16 Million | Skr-45.02 Million |
| Investing Cash Flow | Skr-129.00K | Skr0.00 | Skr96.00K | Skr-260.00K | Skr-260.00K |
| Financing Cash Flow | Skr48.11 Million | Skr45.15 Million | Skr33.61 Million | Skr23.06 Million | Skr76.37 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | Skr48.00K | Skr193.00K | Skr193.00K | Skr193.00K | Skr192.00K |
| Change in Cash | Skr11.06 Million | Skr-5.08 Million | Skr-9.70 Million | Skr-18.36 Million | Skr31.35 Million |
Annexin Pharmaceuticals AB Earnings History — EPS Actual vs. Analyst Estimates
Track Annexin Pharmaceuticals AB's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | -1.48 | — | — |
| Dec 31, 2025 | -1.49 | — | — |
| Sep 30, 2025 | -1.40 | — | — |
| Jun 30, 2025 | -1.20 | — | — |
| May 14, 2025 | -1.48 | — | — |
| Feb 06, 2025 | -2.26 | — | — |
| Oct 17, 2024 | -2.00 | — | — |
| Jul 18, 2024 | -0.04 | — | — |